These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2019-003756-37 A Multicenter, Randomized, Open-Label, Blinded Endpoint Evaluation, Active-Controlled, Dose-Ranging Study to Compare the Efficacy and Safety of i.v. MAA868 and s.c. Enoxaparin in Adult Patients Underg... 2021-03-12 due-trials
Other 2020-004507-13 A Multicenter, Randomized, Active-Controlled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab (MAA868) Compared with Open-Label Rivaroxaban in Patients with Atrial Fibr... not-yet-due
Ongoing 2021-003076-14 A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in pat... not-yet-due
Ongoing 2021-003085-12 A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in p... not-yet-due